LY01008
Monoclonal antibody
Evidence outlook
Approved: Advanced, metastatic or recurrent non-small-cell lung cancer and metastatic colorectal... (CN)
This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
track record: Reliable signal
Also approved (1)
- Advanced, metastatic or recurrent non-small-cell lung cancer and metastatic colorectal cancer (Boyounuo, bevacizumab biosimilar)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03533127 NCT03533127 · Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Recurrent This was a randomized, double-blind, active-controlled equivalence trial in 648 patients that measured objective tumor response rate, using the same paclitaxel/carboplatin backbone in both arms. LY01008's response rate was statistically equivalent to bevacizumab's, within the prespecified margin, meeting the trial's own equivalence criterion. Registry: NCT03533127 | 3 | Best Objective Response Rate (19 weeks from randomization) 2020-06-28 | LY01008 vs Avastin (bevacizumab) + paclitaxel/carboplatin, first-line non-squamous NSCLC: ORR 48.5% vs 53.0%; stratified ORR ratio 0.91 (90% CI 0.80-1.04), within prespecified equivalence margin 0.75-1.33 -> equivalence/non-inferiority demonstrated. | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other VEGF-A drugs
Aflibercept, aflibercept-abzv (Enzeevu), aflibercept-ayyh (Pavblu), aflibercept-boav (Eydenzelt), aflibercept-jbvf (Yesafili) and 33 more. Compare all 39 VEGF-A drugs
This mechanism is crowded: 38 other tracked programmes target it, 20 of them ahead of this one.
This drug's own stage for Colorectal Cancer: Phase 1. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| LY01008: this drug | Phase 1 | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept (Eylea) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF) | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept-Abzv (Enzeevu) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept-Ayyh (Pavblu) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept-Boav (Eydenzelt) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept-Jbvf (Yesafili) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept-Mrbb (Ahzantive) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept-Yszy (Opuviz) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Brolucizumab-Dbll | Approved(overall) | Antibody fragment | VEGF-A | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Capecitabine | ApprovedUS marketing discontinued | Small molecule | Fluoropyrimidine (antimetabolite) | not yet graded | No reviewed efficacy summary in this indication | |
| Encorafenib | Approved | Small molecule | BRAF V600E | not yet graded | No reviewed efficacy summary in this indication | |
| Fruquintinib (Fruzaqla / Elunate) | Approved | Small molecule | VEGFR1/2/3 | Reliable signal | NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001 NCT02314819: Median overall survival 9.3 months with fruquintinib (95% CI 8.2 to 10.5) vs 6.6 months with placebo (95% CI 5.9 to 8.1); HR 0.65 (95% CI 0.51 to 0.83), P<.001 (published analysis) | |
| Ipilimumab | Approved | Monoclonal antibody | CTLA-4 antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Jobevne (bevacizumab-Nwgd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Nivolumab | Approved | Monoclonal antibody | PD-1 | Weak signal | No reviewed efficacy summary in this indication | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Weak signal | NCT02460198: Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Cohort A - Pembrolizumab 200 mg 32.8 Percentage of participants (95% CI 21.3 to 46) | Cohort B - Pembrolizumab 200 mg 34.9 Percentage of participants (95% CI 23.3 to 48) | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Ramucirumab | Approved | Monoclonal antibody | VEGFR2 | Partial signal | NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7) | |
| Ranibizumab (Lucentis) | Approved(overall) | Antibody fragment | VEGF-A | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Ranibizumab-Eqrn (Cimerli) | Approved(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ranibizumab-Hkdz (Ranluspec) | Approved(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ranibizumab-Leyk (Nufymco) | Approved(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ranibizumab-Nuna (Byooviz) | Approved(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Regorafenib | Approved | Small molecule | Multi-kinase inhibitor (VEGFR/PDGFR/KIT) | Reliable signal | NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016) | |
| Sotorasib | Approved | Small molecule | KRAS G12C | not yet graded | No reviewed efficacy summary in this indication | |
| Tucatinib | Approved | Small molecule | HER2 | Partial signal | NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5) | |
| Vegzelma (bevacizumab-Adcd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Zirabev (bevacizumab-Bvzr) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Amivantamab | Phase 3 | Multispecific antibody | EGFR x c-MET | not yet graded | No reviewed efficacy summary in this indication | |
| Anbenitamab Repodatecan | Phase 3 | Antibody–drug conjugate | HER2 (biparatopic — extracellular domains II and IV) | not yet graded | No reviewed efficacy summary in this indication | |
| BAT5906 | Phase 3(overall) | Monoclonal antibody | VEGF-A | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Becotatug | Phase 3 | Monoclonal antibody | EGFR | not yet graded | No reviewed efficacy summary in this indication | |
| Botensilimab | Phase 3 | Monoclonal antibody | CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Chidamide | Phase 3 | Small molecule | HDAC | not yet graded | No reviewed efficacy summary in this indication | |
| CKD-701 (Lucenbies) | Phase 3(overall) | Monoclonal antibody | VEGF-A | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| HLX04 (Hanbeitai) | Phase 3 | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| HLX04-O | Phase 3(overall) | Monoclonal antibody | VEGF-A | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| IBI363 | Phase 3 | Multispecific antibody | PD-1 x IL-2Rα (IL2RA) | not yet graded | No reviewed efficacy summary in this indication | |
| INCA33890 | Phase 3 | Multispecific antibody | TGF-βR2 and PD-1 (conditional bispecific) | not yet graded | No reviewed efficacy summary in this indication | |
| PF-08634404 | Phase 3 | Multispecific antibody | PD-1 + VEGF | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab (Ximluci) | Phase 3(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| S-1 | Phase 3 | Small molecule | Thymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil) | not yet graded | No reviewed efficacy summary in this indication | |
| Surabgene Lomparvovec | Phase 3(overall) | Gene therapy / editing | VEGF-A | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Tarcocimab Tedromer | Phase 3(overall) | Monoclonal antibody | VEGF-A | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Telisotuzumab Adizutecan | Phase 3 | Antibody–drug conjugate | MET | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Brengitecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Rezetecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Zanzalintinib | Phase 3 | Small molecule | VEGFR2; MET; AXL; MER; TYRO3 | not yet graded | No reviewed efficacy summary in this indication | |
| MW02 | Phase 2/3(overall) | Monoclonal antibody | VEGF-A | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| N-Dihydrogalactochitosan | Phase 2/3 | Polysaccharide | STING and inflammasome pathways | not yet graded | No reviewed efficacy summary in this indication | |
| DSP107 | Phase 2 | Protein / enzyme therapeutic | SIRP-alpha/4-1BBL fusion protein | not yet graded | No reviewed efficacy summary in this indication | |
| IBI305 | Phase 2 | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Sirexatamab | Phase 2 | Monoclonal antibody | DKK1 (Dickkopf-1) | not yet graded | No reviewed efficacy summary in this indication | |
| A2B530 | Phase 1/2 | Cell therapy | CEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker) | not yet graded | No reviewed efficacy summary in this indication | |
| NC410 | Phase 1/2(overall) | Protein / enzyme therapeutic | Collagen (LAIR-1 ligands) | not yet graded | No reviewed efficacy summary in this indication | |
| BBO-10203 | Phase 1 | Small molecule | RAS:PI3Kα protein-protein interaction | not yet graded | No reviewed efficacy summary in this indication | |
| CRX100 | Phase 1 | Cell therapy | Cell-based oncolytic virus immunotherapy | not yet graded | No reviewed efficacy summary in this indication | |
| KRAS-Specific Autologous TCR-T Cell | Phase 1(overall) | Cell therapy | KRAS G12V presented on HLA-A*11:01 | not yet graded | No reviewed efficacy summary in this indication | |
| LY4066434 | Phase 1(overall) | Small molecule | Pan-KRAS | not yet graded | No reviewed efficacy summary in this indication | |
| Palupiprant | Phase 1 | Small molecule | EP4 | Weak signal | No reviewed efficacy summary in this indication | |
| PF-07934040 | Phase 1(overall) | Small molecule | Pan-KRAS | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab (Rimmyrah) | Phase 1(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Tusamitamab Sonditecan | Phase 1 | Antibody–drug conjugate | CEACAM5 | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept (Afiveg) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept (Eyluxvi) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept (Mynzepli) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept (Vgenfli) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| PI3Kalpha Precision Therapy | —(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab (Ranivisio) | —(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ranibizumab (Rexatilux) | —(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Telbermin | Discontinued | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication |
Compare side by side
4 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.